Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nasus PharmaNSRX +1.75%14 EV-to-EBITDA is -3.55 as of Aug. 25, 2026. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 735 Drug Manufacturers companies, Nasus Pharma ranks worse than 136054.29% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nasus Pharma's enterprise value is $35.95 Mil.
Nasus Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-10.13 Mil. Therefore, Nasus Pharma's EV-to-EBITDA for today is -3.55.
The historical rank and industry rank for Nasus Pharma's EV-to-EBITDA or its related term are showing as below:
NSRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.55 Med: 0 Max: 0
Current: -3.55
NSRX's EV-to-EBITDA is ranked worse than 100% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.46
vs NSRX: -3.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nasus Pharma's PE Ratio (TTM) for today is calculated as:
Nasus Pharma's share price for today is $4.07.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nasus Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.051.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Nasus Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Nasus Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nasus Pharma EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nasus Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nasus Pharma's EV-to-EBITDA falls into.
Nasus Pharma's current Enterprise Value is $35.95 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nasus Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-10.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nasus Pharma (NSRX) has a EV-to-EBITDA of -3.55 as of Aug. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nasus Pharma. According to the industry distribution chart, Nasus Pharma ranks #999999 out of 735 companies in the Drug Manufacturers industry.
Is Nasus Pharma's EV-to-EBITDA too high?
Nasus Pharma's current EV-to-EBITDA is -3.55. Based on the distribution chart, Nasus Pharma ranks #999999 out of 735 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's EV-to-EBITDA compare to MIRA and SCLX?
According to the Drug Manufacturers industry distribution chart, Nasus Pharma ranks #999999 out of 735 companies for EV-to-EBITDA. This places Nasus Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 13.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.46, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nasus Pharma. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nasus Pharma's current EV-to-EBITDA is -3.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current EV-to-EBITDA of -3.55. The current EV-to-EBITDA is -3.55. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current EV-to-EBITDA is -3.55 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score
Get the complete analysis for NSRX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSRX has been successfully added to your 
